Krystal Biotech vs MeiraGTx
KRYS and MGTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KRYS and MGTX compare
Krystal Biotech is the larger company, worth 11 times as much as MeiraGTx ($9.8B against $911M).
On earnings, MeiraGTx is cheaper: it trades at 13.4× trailing earnings, against 41.6× for Krystal Biotech.
MeiraGTx grew revenue faster over the last twelve months (948% versus 22.6% for Krystal Biotech).
Krystal Biotech keeps more of each dollar of sales as profit, with a net margin of 54.8% compared with 19.9% at MeiraGTx.
MeiraGTx scores higher on the StockData Score (13 against 10 for Krystal Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KRYS | MGTX |
|---|---|---|
| Size and price | ||
| Market cap | $9.8B | $911M |
| Share price | $332.29 | $9.49 |
| Change, 1 year | 79.6% | 6.3% |
| Change, 5 years | 548% | −54.1% |
| Beta (5Y) | 0.84 | 1.58 |
| Employees | 295 | 403 |
| StockData Score | ||
| Total score | 10 | 13 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 41.6× | 13.4× (better) |
| P/S | 22.3× | 2.3× (better) |
| P/B | 7.2× | – |
| EV/EBITDA | 45.5× | 4.4× (better) |
| P/FCF | 38.2× (better) | 87.1× |
| FCF yield | 2.6% (better) | 1.1% |
| Fair value | $157.63 | $24.09 |
| Margin of safety | −111% | 60.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 22.6% | 948% (better) |
| Revenue growth, 5Y average | – | 39.2% |
| Net income growth (TTM) | 64.6% | – |
| EPS growth (TTM) | 62.2% | – |
| Profitability | ||
| Operating margin | 44.9% | 46.3% (better) |
| Net margin | 54.8% (better) | 19.9% |
| FCF margin | 58.5% (better) | 2.6% |
| Return on equity | 20.1% | 2668% (better) |
| Return on invested capital | 45.3% | 344% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | −0.22 |
| Interest coverage | – | 14.7× |
| Current ratio | 8.32 (better) | 3.76 |
| Altman Z-score | 43.30 (better) | 3.57 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | −14.6% |
| Shareholder yield | 0.00% (better) | −14.6% |
| Ownership | ||
| Held by institutions | 102% | 82.5% |
| Held by insiders | 17.2% | 35.3% |
| Insider net buying, 12 months | −$105M | −$3.8M (better) |
| Short interest, % of float | 14.2% | 9.6% |
Go deeper
- KRYS stock overview
- KRYS income statement
- KRYS valuation and score
- MGTX stock overview
- MGTX income statement
- MGTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.